STUDY OF VANCOMYCIN RESISTANCE AMONG STAPHYLOCOCCUS AUREUS

Barra lateral de artigos

PDF (English)
Publicado: abr 30, 2019
DOI: https://doi.org/10.14295/aimj.v3i6.58

Conteúdo do artigo principal

Victor Victor Campos de Albuquerque
Universidade Estadual do Piauí - UESPI
Vicente Clinton Justiniano Flores
Universidade de Santo Amaro - UNISA
Rubens Moura Campos Zeron
Centro Universitário Lusíada - UNILUS
Bruno Bastos Godoi
Federal University of Vales do Jequitinhonha e Mucuri – UFVJM –MG, Brazil
Walberto Monteiro Neiva Eulálio Filho
Universidade Federal do Piauí - UFPI
Bruna Afonso dos Santos
Centro Universitário Uninovafapi

Resumo

Staphylococcus aureus (S.aureus) infections with Vancomycin resistance in hospital complexes are a concern, a significant increase in the number of these occurrences is observed since it is one of the last available antibiotic therapy routes available for the treatment of infectious processes bacterium. Thus, this work aims to present the main mechanism of resistance induction of S. aureus to Vancomycin. The research used the databases Medline, Scielo, the electronic site of the Google Scholar databases as well as specialized magazines in the area. Thus, the selected articles showed that in the late 1950s almost half of S. aureus strains were resistant to penicillin, and in the 1970s the first cases of methicillin-resistant S. aureus (MRSA) appeared; and thus, Vancomycin became employed in such cases. In 1996, the first case of S. aureus with intermediate resistance to vancomycin (VISA) was found. In 2002, the first case of Vancomycin-resistant S. aureus (VRSA) occurred, the latter being the only known to have the VanA gene until then. It was soon discovered that the emergence of this resistance occurred from the transfer of a plasmid with the transposon of the vancomycin resistant vanA, Tn1546 vancomycin (VRE) gene to an MRSA, which already had a plasmid for resistance to gentamicin and production of beta-lactamase. This new plasmid was disseminated to other S. aureus and thus disseminating a new resistance. Thus, the conclusion is that the cycle repeats itself and previously sensitive bacteria become resistant; thus, in this rhythm of emergence of bacterial resistance against antibiotic therapy is worrying, there will be a moment when there will be no antibiotic capable of acting in the fight against bacteria. This shows the need to understand the mechanism of resistance, the discovery of new antimicrobial drugs and the prevention of the spread of resistant microbes.

Key words: Staphylococcus aureus, vancomycin, microbial drug resistance, vancomycin resistance.

Métricas

Carregando Métricas ...

Detalhes do artigo

Como Citar
Albuquerque, V. V. C. de, Flores, V. C. J., Zeron, R. M. C., Godoi, B. B., Eulálio Filho, W. M. N., & Santos, B. A. dos. (2019). STUDY OF VANCOMYCIN RESISTANCE AMONG STAPHYLOCOCCUS AUREUS. Amadeus International Multidisciplinary Journal, 3(6), 31–37. https://doi.org/10.14295/aimj.v3i6.58
Edição
v. 3 n. 6 (2019)
Seção
Review article

Esta licença permite que os reutilizadores distribuam, remixem, adaptem e construam sobre o material em qualquer meio ou formato apenas para fins não comerciais e apenas enquanto a atribuição for dada ao criador. 

Biografia do Autor

Victor Victor Campos de Albuquerque, Universidade Estadual do Piauí - UESPI

1 State University of Piauí – UESPI – PI, Brazil; Contact: victoralbuquer@gmail.com

Vicente Clinton Justiniano Flores, Universidade de Santo Amaro - UNISA

2 Santo Amaro University – UNISA – SP, Brazil;

Rubens Moura Campos Zeron, Centro Universitário Lusíada - UNILUS

3 Lusíada University Center – UNILUS – SP, Brazil;

Bruno Bastos Godoi, Federal University of Vales do Jequitinhonha e Mucuri – UFVJM –MG, Brazil

4 Federal University of Vales do Jequitinhonha e Mucuri – UFVJM –MG, Brazil;

Walberto Monteiro Neiva Eulálio Filho, Universidade Federal do Piauí - UFPI

5 Federal University of Piauí – UFPI – PI, Brazil;

Bruna Afonso dos Santos, Centro Universitário Uninovafapi

6 Uninovafapi University Center – PI, Brazil;

Referências

Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. [Review] J Clin Invest 2003;111:1265-73.

Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in Staphylococci. Epidemiology, molecular mechanisms and clinical relevance. [Review] Infect Dis Clin North Am 1997;11:813-49.

Jessen O, Rosendal K, Bulow P, Faber V, Eriksen KR. Changing staphylococci and staphylococcal infections: A ten-year study of bacteria and cases of bacteremia. N Engl J Med 1969;281:627-35.

Schito GC. The importance of the development of antibiotic resistance in Staphylococcus aureus.[Review] Clin Microbiol Infect 2006;12(Suppl. 1):3-8.

Chambers HF. The changing epidemiology of Staphylococcus aureus?[Review] Emerg Infect Dis 2001;7:178-82.

van Belkum A, Verbrugh H. 40 years of methicillin resistant Staphylococcus aureus. MRSA is here to stay-but it can be controlled [Editorial]. BMJ 2001;323:644-5.

Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin resistance Staphylococcus aureus. [Review] Lancet Infect Dis 2002;2:180-9.

Farr BM. Prevention and control of methicillin-resistant Staphylococcus aureus infections. [Review] Curr Opin Infect Dis 2004;17:317-22.

DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest. 2009;119(9):2464–2474.

Maple PA, Hamilton-Miller JM, Brumfitt W. Worldwide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet. 1989;1(8637):537–540.

27. Geraci, J. E. 1956. Some laboratory and clinical experiences with a new antibiotic, vancomycin. p. 90–106. In Antibiotic annual 1955-1956. Medical Encyclopedia, New York, N.Y.

Ziegler, D. W. 1956. Vancomycin, a new antibiotic II. In vitro antibacterial studies, p. 612–618. In Antibiotic annual 1955-1956. Medical Encyclopedia, New York, N.Y.

Moellering, R. C. 1998. The specter of glycopeptide resistance: current trends and future considerations. Am. J. Med. 104(Suppl. 5A):3S–6S.

Ena, J., R. W. Dick, R. N. Jones, and R. P. Wenzel. 1993. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA 269:598–602.

Siebert, W. T., N. Moreland, and T. W. Williams, Jr. 1979. Synergy of vancomycin plus cefazolin or cephalothin against methicillin-resistance Staphylococcus epidermidis. J. Infect. Dis. 139:452–457.

Tuazon, C. U., and H. Miller. 1983. Clinical and microbiologic aspects of serious infections caused by Staphylococcus epidermidis. Scand. J. Infect. Dis. 15:347–360.

Centers for Disease Control and Prevention. 1997. Reduced susceptibility of Staphylococcus aureus to vancomycin—Japan, 1996. Morb. Mortal. Wkly. Rep. 46:624–626.

Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135–136.

Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, and W. R. Jarvis. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N. Engl. J. Med. 340:493–501.

Fridkin SK. Vancomycin intermediate and resistant S aureus: What infectious disease specialists need to know. Clin Infect Dis. 2001;32:429–39.

BREVES; Angela; Catia A C, MIRANDA; Claudia, FLORE; Ivano DE, FILIPPIS; Maysa M, CLEMENTINO. Methicillin- and vancomycin- resistant Staphylococcus aureus in health care workers and medical devices. J. Bras. Patol. Med. Lab. Rio de Janeiro, v. 51, n. 3, p. 143- 152, 2015.

Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.

Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998;42:199-209.

Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998;36:1020-7.

Rossi F, Andreazzi DB (2005) Resistência Bacteriana: Interpretando o Antibiograma. Atheneu, São Paulo, 118 pp.

Cui L, Iwamoto A, Lian J, Neoh H, Mmaruyama T, Horikawa Y, Hiramatsu K (2006) Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50:428-238.

Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-8.

Ray AJ, Pultz NJ, Bhalla A, Aron DC, Donskey CJ. Coexistence of vancomycin-resistant enterococci and Staphylococcus aureus in the intestinal tracts of hospitalized patients. Clin Infect Dis 2003;37:875-81.

Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes PH. Infection with vancomycinresistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-7.

Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureusPennsylvania, 2002. MMWK Morb Mortal Wkly Rep 2002;51:902-3.

Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus-New York, 2004. MMWK Morb Mortal Wkly Rep 2004;53:322.

Walsh CT. Vancomycin resistance: decoding the molecular logic. Science 1993;261:308-9.

Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagan SE et al. Genetic analysis of a high level vancomycin-resistant isolate of Staphylococcus aureus. Science 2003;302:1569-71.

Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001;1:147-55.

Anderson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999;2:489-93.

Tabaqchali S. Vancomycin-resistant Staphylococcus aureus: apocalypse now? Lancet 1997;350:1644-5.

Bush K. Vancomycin-resistant Staphylococcus aureus in the clinic: not quite Armageddon. Clin Infect Dis 2004;38:1056-7.